Diabetes microvascular complications—A clinical update

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 11, Issue , 2017, Pages S133-S139

  Khalil, H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Management; Nephropathy; Neuropathy; Pathogenesis; Retinopathy

Indexed keywords

BLOOD PRESSURE; CLINICAL PRACTICE; COCHRANE LIBRARY; DIABETIC COMPLICATION; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; GLYCEMIC CONTROL; HUMAN; KIDNEY DISEASE; MEDLINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOPATHY; REVIEW; RISK FACTOR; COMPLICATION; INSULIN DEPENDENT DIABETES MELLITUS; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; VASCULAR DISEASE;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; MICROVESSELS; VASCULAR DISEASES;

EID: 85007564449     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2016.12.022     Document Type: Review

References (55)

1. Chung, S.S.M., Chung, S.K., Aldose reductase in diabetic microvascular complications. Curr Drug Targets 6:4 (2005), 475–486.
2. Rossing, Peter, Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 6:6 (2006), 479–483.
3. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 1 (2010), S62–S69.
4. American Diabetes Association, Economic costs of diabetes in the US in 2007. Diabetes Care 3 (2008), 596–615.
5. Li, T.C., Kardia, S.L., Li, C.I., Chen, C.C., Liu, C.S., Yang, S.Y., et al. Glycemic control paradox: poor glycemic control associated with higher one-year and eight-year risks of all-cause hospitalization but lower one-year risk of hypoglycemia in patients with type 2 diabetes. Metabolism 64:September (9) (2015), 1013–1021 30.
6. Zoungas, S., Chalmers, J., Ninomiya, T., Li, Q., Cooper, M.E., Colagiuri, S., et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 55:March (3) (2012), 636–643 1.
7. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:June (6) (2012), 1577–1596 1.
8. Zhiheng, He, King, George L., Microvascular complications of diabetes. Endocrinol Metab Clin, 33, 2004, 1.
9. Lin, E.H., Rutter, C.M., Katon, W., Heckbert, S.R., Ciechanowski, P., Oliver, M.M., et al. Depression and advanced complications of diabetes. a prospective cohort study. Diabetes Care 33:2 (2010), 264–269.
10. Raman, R., Gupta, A., Krishna, S., Kulothungan, V., Sharma, T., Prevalence and risk factors for diabetic microvascular complications in newly diagnosed type II diabetes mellitus. J Diabetes Complicat 26:2 (2012), 123–128.
11. Zoungas, S., Woodward, M., Li, Q., Cooper, M.E., Hamet, P., Harrap, S., et al. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia 57:December (12) (2014), 2465–2474 1.
12. Krolewski, A.S., Warram, J.H., Rand, L.I., Kahn, C.R., Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med 317 (1987), 1390–1398.
13. Jerneld, B., Algvere, P., Relationship of duration and onset of diabetes to prevalence of diabetic retinopathy. Am J Ophthalmol 102 (1986), 431–437.
14. Zochodne, D.W., Malik, R.A., Mechanisms of diabetic neuropathy: schwann cells. Aminoff, Boller, Swaab, (eds.) Diabetes and the Nervous System: Handbook of Clinical Neurology, 126, 2014, 401.
15. Tesfaye, S., Chaturvedi, N., Eaton, S.E., Ward, J.D., Manes, C., Ionescu-Tirgoviste, C., et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 352:4 (2005), 341–350.
16. Callaghan, Brian C., Cheng, Hsinlin T., Stables, Catherine L., Smith, Andrea L., Feldman, Eva L., Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 6 (2012), 521–534.
17. Franco, L.C., Souza, L.A., Pessoa, A.P., Pereira, L.V., Nonpharmacologic therapies in diabetic neuropathic pain: a review. Acta Paulista de Enfermagem 24:2 (2011), 284–288.
18. Khalil, Hanan, Painful diabetic neuropathy management. Int J Evid‐Based Healthcare 11:1 (2013), 77–79.
19. Cohen, K., Shinkazh, N., Frank, J., Israel, I., Fellner, C., Pharmacological treatment of diabetic peripheral neuropathy. Pharmacy Ther 40:6 (2015), 372–388.
20. van Nooten, F.E., Charokopou, M., Poole, C., Treur, M., A systematic literature review and network meta-analysis of capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy. Value Health, 18(Novrmber (7)), 2015, A659 1.
21. Spallone, V., Management of painful diabetic neuropathy: guideline guidance or jungle?. Curr Diab Rep 12 (2012), 403–413.
22. Saaddine, J.B., Honeycutt, A.A., Narayan, K.V., Zhang, X., Klein, X.R., Boyle, J.P., Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. Arch Ophthalmol 126:12 (2008), 1740–1747.
23. Franklin, S.W., Rajan, S.E., Diagnosis of diabetic retinopathy by employing image processing technique to detect exudates in retinal images. IET Image Process 8:October (10) (2014), 601–609.
24. Zhang, X., Wang, N., Schachat, A.P., Bao, S., Gillies, M.C., Glucocorticoids: structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema. Current Mol Med 14:3 (2014), 376–384.
25. UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 31 (1998), 7160–7703.
26. Nordwall, M., Abrahamsson, M., Dhir, M., Fredrikson, M., Ludvigsson, J., Arnqvist, H.J., Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden). Diabetes Care 38:February (2) (2015), 308–315 1.
27. Do, D.V., Wang, X., Vedula, S.S., Marrone, M., Sleilati, G., Hawkins, B.S., et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev(1), 2015, CD006127, 10.1002/14651858.cd006127.pub2.
28. Keech, A.C., Mitchell, P., Summanen, P.A., O'Day, J., Davis, T.M., Moffitt, M.S., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370:November (9600) (2007), 1687–1697 23.
29. ACCORD Study Group, ACCORD Eye Study Group, Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010:July (363) (2010), 233–244 15.
30. Wang, B., Wang, F., Zhang, Y., Zhao, S.H., Zhao, W.J., Yan, S.L., et al. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 3:April (4) (2015), 263–274 30.
31. Abbate, M., Cravedi, P., Iliev, I., Remuzzi, G., Ruggenenti, P., Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives. Curr Diabetes Rev 7:3 (2011), 190–200.
32. LambersHeerspink, H.J., Johnsson, E., Gause-Nilsson, I., Johannson, K., Sjostrom, C.D., Dapagliflozin reduces albuminuria on top of renin-angiotensin system blockade in hypertensive diabetic patients [Poster 1176-P]. Diabetes, 64, 2015, A303.
33. Zhang, X., Wang, N., Schachat, A.P., Bao, S., Gillies, M.C., Glucocorticoids: structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema. Curr Mol Med 14:March (3) (2014), 376–384 1.
34. Solomon, S.D., Lindsley, K., Vedula, S.S., Krzystolik, M.G., Hawkins, B.S., Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev(8), 2014, CD005139, 10.1002/14651858.cd005139.pub3.
35. Raczyńska, D., Zorena, K., Urban, B., Zalewski, D., Skorek, A., Malukiewicz, G., et al. Current trends in the monitoring and treatment of diabetic retinopathy in young adults. Mediators Inflamm(February (13)), 2014.
36. Stavniichuk, R., Shevalye, H., Lupachyk, S., Obrosov, A., Groves, J.T., Obrosova, I.G., et al. Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy. Diabetes Metab Res Rev 30:8 (2014), 669–678.
37. Hajhosseiny, R., Khavandi, K., Jivraj, N., Mashayekhi, S., Goldsmith, D.J., Malik, R.A., Have we reached the limits for the treatment of diabetic nephropathy?. Expert Opin Investig Drugs 23:4 (2014), 511–522.
38. Suckling, R.J., He, F.J., Macgregor, G.A., Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev, 12(December (8)), 2010, CD006763.
39. DCCT Research Group, Factors in development of diabetic neuropathy: baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). Diabetes 37:4 (1988), 476–481.
40. Fineberg, D., Jandeleit-Dahm, K.A., Cooper, M.E., Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol 9:December (12) (2013), 713–723 1.
41. Yamout, H., Bakris, G.L., Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy. Nat Rev Nephrol 18:July (2016), 583–584.
42. Heerspink, H.J., Holtkamp, F.A., Parving, H.H., Navis, G.J., Lewis, J.B., Ritz, E., et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012:March 21 (2012), 330–337.
43. Escobar, C., Echarri, R., Barrios, V., Emerging drug combinations to optimize renovascular protection and blood pressure goals. Int J Nephrol Renovasc Dis 5 (2012), 69–80.
44. Yorek Mark, A., Oxidative Stress and Diabetes-Induced Vascular Dysfunction: Role in Diabetic Neuropathy Studies in Diabetes. 2014, Springer, New York, 1–12.
45. Cumbie, Brian C., Hermayer, Kathie L., Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications. Vasc Health Risk Manag 3:December (6) (2007), 823–832.
46. Akileshwari, C., Raghu, G., Muthenna, P., Mueller, N.H., Suryanaryana, P., Petrash, J.M., et al. Bioflavonoid ellagic acid inhibits aldose reductase: implications for prevention of diabetic complications. J Funct Foods 6 (2014), 374–383.
47. Parving, Hans-Henrik, Rossing, Peter, Diabetic nephropathy in 2014: Improved cardiorenal prognosis in diabetic nephropathy. Nat Rev Nephrol 11:2 (2014), 68–70.
48. Oyenihi, A.B., Ayeleso, A.O., Mukwevho, E., Masola, B., Antioxidant strategies in the management of diabetic neuropathy. BioMed Res Int, 2015(March (2)), 2015.
49. Fakhrabadi, M.A., Ghotrom, A.Z., Mozaffari-Khosravi, H., Nodoushan, H.H., Nadjarzadeh, A., Effect of coenzyme Q10 on oxidative stress, glycemic control and inflammation in diabetic neuropathy: a double blind randomized clinical trial. Int J Vitam Nutr Res 84:January (5–6) (2014), 252–260 1.
50. House, A.A., Eliasziw, M., Cattran, D.C., Churchill, D.N., Oliver, M.J., Fine, A., et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303:April (16) (2010), 1603–1609 28.
51. Tuttle, K.R., McGill, J.B., Bastyr, E.J., Poi, K.K., Shahri, N., Anderson, P.W., Effect of ruboxistaurin on albuminuria and estimated GFR in people with diabetic peripheral neuropathy: results from a randomized trial. Am J Kidney Dis 65:April (4) (2015), 634–636 1.
52. Papanas, Nikolaos, Ziegler, Dan, Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother 15:18 (2014), 2721–2731.
53. Zhou, J.Y., Zhang, Z., Qian, G.S., Mesenchymal stem cells to treat diabetic neuropathy: a long and strenuous way from bench to the clinic. Cell Death Discov, 2, 2016, 16055.
54. Dworkin, R.H., O'connor, A.B., Backonja, M., Farrar, J.T., Finnerup, N.B., Jensen, T.S., et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132:3 (2007), 237–251.
55. Kim, D.J., Summary of the american diabetes association standards of medical care in diabetes 2012. J Korean Diabetes 13:March (1) (2012), 7–14 1.